MedTrace Logo

Effects of 5-Aminolevulinic Acid on Iron Deficiency Anemia

NCT01380548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2013-03-28

No results posted yet for this study

Summary

This study is designed to evaluate efficacy and dose-dependency of 5-aminolevulinic acid in subjects with iron deficiency anemia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Placebo; once/day; for 12 weeks

DIETARY_SUPPLEMENT

Iron alone

Iron (3 mg); once/day; for 12 weeks

DIETARY_SUPPLEMENT

Low-dose 5-aminolevulinic acid with iron

5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks

DIETARY_SUPPLEMENT

Medium-dose 5-aminolevulinic acid with iron

5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks

DIETARY_SUPPLEMENT

High-dose 5-aminolevulinic acid with iron

5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks

Sponsors & Collaborators

  • SBI ALApromo Co., Ltd., Japan

    collaborator UNKNOWN

  • Hiroshima University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380548 on ClinicalTrials.gov